Life Sciences

  • February 06, 2024

    Calif. Lawmakers Pitch New Psychedelics Treatment Bill

    California lawmakers on Tuesday introduced a bipartisan proposal to regulate the therapeutic administration of nature-derived psychedelics after the governor vetoed a previous proposal last year.

  • February 06, 2024

    10th Circ. Affirms $4.7M Stryker Loss, But Tosses Fee Award

    A Tenth Circuit panel said on Tuesday that medical device maker Stryker is not required to indemnify a Colorado distributor for the cost of winning a lawsuit against it, according to a ruling that upheld a $4.7 million judgment against Stryker but vacated a $2.3 million fee award.

  • February 06, 2024

    Pacira Touts Stability Upgrade In Pain Drug Patent Trial

    A novel manufacturing process that extends the shelf life of the pain reliever Exparel should extend the exclusivity period of the product's patent, Pacira BioSciences Inc. has told a New Jersey judge tasked with weighing infringement claims against generic-drug maker eVenus.

  • February 06, 2024

    Judge Will Screen Ex-CEO's Filings In Stimwave Ch. 11

    A Delaware bankruptcy judge said Tuesday he will require the ex-CEO of Stimwave Technologies and two of her relatives to seek permission from the court before submitting anymore filings in the medical device maker's Chapter 11 case.

  • February 06, 2024

    JPML Consolidates Suboxone Dental Decay Suits In Ohio

    The Northern District of Ohio will host consolidated cases brought against Indivior, Reckitt Benckiser and others alleging the companies failed to warn users of opioid addiction treatment Suboxone that it causes dental decay, according to an order from the U.S. Judicial Panel on Multidistrict Litigation joining 15 suits.

  • February 06, 2024

    6th Circ. Backs Becton's Win In Royalties Suit

    An inventor of medication valves failed to convince the Sixth Circuit to revive his suit alleging that Becton Dickinson & Co. owes him two years' worth of royalties, with the appellate court reasoning Tuesday that a district court properly interpreted the licensing agreement's payout time limit on his patent.

  • February 06, 2024

    NanoString Can Tap $142.5M DIP As It Weighs Ch. 11 Sale

    Life sciences company NanoString Technologies Inc. received a Delaware bankruptcy judge's approval Tuesday to borrow a portion of $142.5 million in Chapter 11 financing that the company will use to support operations while assessing outside offers to buy its business.

  • February 06, 2024

    Freshfields Helps Novartis Buy German Pharma In €2.7B Deal

    Swiss pharmaceutical giant Novartis AG has agreed to buy MorphoSys AG in a deal that values the German biopharmaceutical group at €2.7 billion ($2.9 billion) as it seeks to develop its oncology treatment options.

  • February 05, 2024

    Psychedelics Bill Roundup: Mass. Proposal Enters Legislature

    A citizen-led effort to legalize personal use and possession of natural psychedelics in Massachusetts entered the state Legislature this week, a Hawaii bill to regulate therapeutic use of psilocybin is scheduled for its first hearing, and Indiana lawmakers advanced a bill to fund research into psilocybin treatment. Here are the major developments in psychedelic legislation from the past week.

  • February 05, 2024

    7th Circ. Wary Of Bid To Revive Abbott Formula Claims

    A Seventh Circuit panel on Monday appeared skeptical of a bid to restore claims that parents were harmed economically by buying infant formula that could have been contaminated at an Abbott Laboratories plant, asking how they were injured and whether the risk of contamination alone is enough to survive dismissal.

  • February 05, 2024

    Proposed Class Action Settlement May Cost Acella $46.5M

    A proposed agreement to end a class action over thyroid medication, after a U.S. Food and Drug Administration inspection found products with an active ingredient above and below label specifications, may cost Acella Pharmaceuticals $46.5 million.

  • February 05, 2024

    Biotech Co. Hit With Investor Suit Over Alzheimer's Drug Trial

    Biotechnology company Cassava Sciences and two of its executives were hit with a proposed class action over allegations that a co-developer of the company's Alzheimer's drug was under investigation by his employer for possible data manipulation, which Cassava concealed from the public.

  • February 05, 2024

    Ozempic Injury Suits Consolidated In Eastern Pa. MDL

    The Judicial Panel on Multidistrict Litigation has moved 55 MDL cases over Ozempic and similar drugs to the Eastern District of Pennsylvania, centralizing the litigation that claims Novo Nordisk A/S and Eli Lilly & Co. failed to warn patients about the risks associated with the class of drug.

  • February 05, 2024

    Ga. Sues Federal Gov't Over Medicaid Expansion Program

    Georgia has sued the Biden administration to keep the state's Medicaid program for low-income residents running until 2028, arguing the program was illegally cut short by a federal agency and that its initial five-year term must be honored.

  • February 05, 2024

    Biotech Co. Hits Ch. 11, Blames Drug Misfires, Criminal Case

    DMK Pharmaceuticals has applied for Chapter 11 protection in Delaware, citing recent clinical trial failures and product recalls, as well as the government's allegation that a subsidiary engaged in criminal activities, as reasons for seeking bankruptcy relief.

  • February 05, 2024

    CPAP Cleaner Co. Says Philips Can't Pin Recall On It

    Cleaning products designed to work with Koninklijke Philips NV's breathing machines were not the direct cause of damages the company suffered when it recalled the products, so SoClean could not be subject to false-advertising claims stemming from statements about "compatibility," it told a Pennsylvania federal court.

  • February 05, 2024

    Zymergen Ch. 11 Plan Confirmed After Investor Objection

    Biotechnology company Zymergen received confirmation of its Chapter 11 plan Monday at a hearing in Delaware bankruptcy court after resolving an objection to the plan from a class of investors suing the company.

  • February 05, 2024

    Teva Asks Fed. Circ. To Examine $177M Verdict Reversal

    Teva Pharmaceuticals has urged the Federal Circuit to reverse a Massachusetts federal judge's decision to toss out a $176.5 million migraine drug patent infringement verdict in its favor against Eli Lilly & Co., arguing that the judge's decision was based on "serious legal errors."

  • February 05, 2024

    Gene-Editing Firm Taps IPO Wave With Plans To Raise $100M

    Gene-editing medicines developer Metagenomi Inc. on Monday unveiled a price range on an estimated $100 million initial public offering, represented by Goodwin Procter LLP and underwriters counsel Davis Polk & Wardwell LLP, joining a busy IPO market for life sciences companies.

  • February 05, 2024

    3 Firms Guide Merck Animal Health's $1.3B Buy Of Fish Biz

    Merck Animal Health announced on Monday that it plans to buy Elanco Animal Health's fish welfare business for $1.3 billion in cash, in a deal guided by Covington & Burling LLP, Gibson Dunn & Crutcher LLP and White & Case LLP.

  • February 05, 2024

    Spinal Implant Maker Previews Ch. 11 Sale And Wind Down

    Bankrupt biotechnology developer InVivo Therapeutics Corp. will auction its assets and hopefully propose a Chapter 11 wind down plan in April, attorneys told a Delaware bankruptcy court Monday at a first day hearing.

  • February 05, 2024

    Biotech Co. NanoString Hits Ch. 11 In Del. With $325M Debt

    Life sciences company NanoString Technologies Inc. and three affiliates filed for Chapter 11 protection in Delaware bankruptcy court with $325 million in debt and $275 million in assets, months after a jury found it infringed several gene-technology patents.

  • February 05, 2024

    Novo Holdings Buying Biopharma Co. Catalent In $16.5B Deal

    Novo Holdings, the controlling shareholder in Novo Nordisk Foundation, said Monday it has agreed to acquire Catalent in an all-cash transaction that values the pharmaceutical company at $16.5 billion, including debt, about five months after Catalent struck a deal with activist investor Elliott Investment Management to conduct a strategic review. 

  • February 02, 2024

    Eli Lilly, Sanofi Beat Antitrust Suit Alleging Insulin Conspiracy

    A New York federal judge on Thursday tossed an antitrust suit alleging major drug manufacturers conspired to retract insulin discounts to boost profits, saying the companies developed their drug policies separately and not in conjunction with one another.

  • February 02, 2024

    McKinsey's $78M Opioid Deal With Health Plans Hits Snag

    A California federal judge considering a $78 million deal between third-party payors and McKinsey & Co. in multidistrict litigation over the consulting firm's marketing advice to opioid makers held off on preliminarily approving the deal Friday, instead setting a new hearing date after some plaintiffs' attorneys raised issues with aspects of the deal.

Expert Analysis

  • Series

    Children's Book Writing Makes Me A Better Lawyer

    Author Photo

    Becoming a children's book author has opened doors to incredible new experiences of which I barely dared to dream, but the process has also changed my life by serving as a reminder that strong writing, networking and public speaking skills are hugely beneficial to a legal career, says Shaunna Bailey at Sheppard Mullin.

  • How The PTAB Landscape Shifted In 2023

    Author Photo

    Attorneys at Finnegan consider the impact of noteworthy Patent Trial and Appeal Board developments in 2023, including rulemaking, litigation, precedential decisions and director reviews that affected PTAB practice, and offer a reference for examining future proceedings and strategies.

  • New Pharma Guidelines Bring Pitfalls For Compounders

    Author Photo

    New guidelines from U.S. Pharmacopeia, which went into effect last month, require some extensive and potentially expensive compliance efforts from hospitals and compounding pharmacies, and smaller compounders could particularly struggle, says Natalia Mazina at Mazina Law.

  • Opinion

    What Happens If High Court Rejects Releases In Purdue Ch. 11

    Author Photo

    Reading the tea leaves following the U.S. Supreme Court's recent arguments in Harrington v. Purdue Pharma, it appears likely that the justices will decide that bankruptcy courts lack the power to release third-party claims against nondebtors, which would result in one of three scenarios, says Gregory Germain at Syracuse University.

  • FDA's Recent Litigation Records Are Strong, But Imperfect

    Author Photo

    The U.S. Food and Drug Administration has notched its share of litigation wins in recent years thanks to a number of key advantages, but the FDA has been less successful in certain highly visible arenas, Jonathan Berman and Colleen Heisey at Jones Day.

  • Coming To Terms With Means-Plus-Function Patent Claims

    Author Photo

    Made-up patent claim terms can open arguments that means-plus-function claim interpretation applies under the Patent Act, but a series of practice tips, including the use of structural language immediately after introducing a claim element, can help avoid such perceptions, says Brad Luchsinger at Harness IP.

  • 5 Steps For Healthcare Companies After Biden's AI Order

    Author Photo

    Rather than simply monitoring for the issuance of agency guidelines on artificial intelligence in the wake of President Joe Biden's October executive order, health and life sciences companies should take action now and begin building internal operational and technical infrastructures designed to govern the use of AI, says Joy Sharp at Faegre Drinker.

  • Opinion

    Giving The Gov't Drug Patent March-In Authority Is Bad Policy

    Author Photo

    The Biden administration's recent proposal to allow government seizure of certain taxpayer-funded drug patents is a terrible idea that would negate the benefits of government-funded research, to the detriment of patients and the wider economy, says Wayne Winegarden at Pacific Research Institute.

  • How Clients May Use AI To Monitor Attorneys

    Excerpt from Practical Guidance
    Author Photo

    Artificial intelligence tools will increasingly enable clients to monitor and evaluate their counsel’s activities, so attorneys must clearly define the terms of engagement and likewise take advantage of the efficiencies offered by AI, says Ronald Levine at Herrick Feinstein.

  • 7 Enforcement Predictions For US Export Controls, Sanctions

    Author Photo

    Federal agencies' assertions of coming increases in export-control and sanctions-violations enforcement are not new, but recent improvements in resources and inter-agency cooperation allow for certain predictions about how the administration’s latest approach to enforcement may be applied going forward, say attorneys at Akin.

  • How AI Executive Order Aims To Compete For Foreign Talent

    Author Photo

    Immigration provisions within the Biden administration's executive order on artificial intelligence take a strategic approach to promoting the U.S. as a destination for AI and STEM talent by streamlining visa processing, enhancing educational and exchange programs, and improving current visa programs and pathways to permanent residency, says Eric Bord at Morgan Lewis.

  • Series

    ESG Around The World: Singapore

    Author Photo

    Singapore is keen to establish itself as a leading international financial center and a key player in the sustainable finance ecosystem, and key initiatives led by its government and other regulatory bodies have helped the Asian nation progress from its initially guarded attitude toward ESG investment and reporting, say attorneys at Morgan Lewis.

  • Series

    The Pop Culture Docket: Judge D'Emic On Moby Grape

    Author Photo

    The 1968 Moby Grape song "Murder in My Heart for the Judge" tells the tale of a fictional defendant treated with scorn by the judge, illustrating how much the legal system has evolved in the past 50 years, largely due to problem-solving courts and the principles of procedural justice, says Kings County Supreme Court Administrative Judge Matthew D'Emic.

  • Navigating Asset Tracing Challenges In Bankruptcy

    Author Photo

    A Virginia court’s recent ruling in Health Diagnostic Laboratory Inc.'s bankruptcy highlights the heightened demand for asset tracing and the strategic use of the lowest intermediate balance rule in recovering funds from commingled accounts, says Daniel Lowenthal at Patterson Belknap.

  • Reading The Fine Print On FDA's Prescription Drug Ad Rule

    Author Photo

    The U.S. Food and Drug Administration's new final rule regarding the disclosure of risks and side effects in ads for prescription drugs includes some broad and potentially subjective language, and some missed opportunities to address how traditional media formats have changed in recent years, say attorneys at Ropes & Gray.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.
Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!